Pre-Exercise Hyperventilation Effects on Wingate Test

August 26, 2026 updated by: Manisa Celal Bayar University

Acute Effects of Pre-Exercise Voluntary Hyperventilation on Ventilatory Kinetics and Anaerobic Performance During a 30-s Wingate Test

This study investigates the acute effects of pre-exercise voluntary hyperventilation on pulmonary gas exchange, cardiovascular responses, and anaerobic performance during a 30-second Wingate test in athletic males using a randomized crossover design.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Background The purpose of this study was to examine how hyperventilation (HV) affected pulmonary gas exchange, cardiovascular responses, and supramaximal performance during a 30-second Wingate Anaerobic Test (WAnT).

Methods In a randomized crossover design, 18 athletic males completed both a control session and an HV session (30 breaths/min for 2 min prior to the WAnT).

Study Type

Interventional

Enrollment (Actual)

18

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
      • Manisa, Turkey (Türkiye), 45040
        • Manisa Celal Bayar University, Faculty of Sport Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Being a healthy male competitive athlete aged 18-26 years
  • Having at least three years of consistent anaerobic training experience
  • Being a nonsmoker

Exclusion Criteria:

  • Having any cardiovascular, musculoskeletal, neurological, or pulmonary disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control Session
Participants performed the 30-second Wingate test under control conditions without pre-exercise hyperventilation
Other: Control Conditions
Participants performed the 30-second Wingate test under control conditions without pre-exercise hyperventilation.
Experimental: Hyperventilation Session
Participants performed voluntary hyperventilation (30 breaths/min for 2 min) prior to the 30-second Wingate test.
Other: Pre-exercise Voluntary Hyperventilation
Participants performed voluntary hyperventilation at a rate of 30 breaths/min for 2 minutes prior to the 30-second Wingate anaerobic test.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Peak Power Output and Mean Power Output during the 30-second Wingate test
Time Frame: During the 30-second Wingate test
During the 30-second Wingate test

Secondary Outcome Measures

Outcome Measure
Time Frame
Pulmonary Gas Exchange responses during the 30-second Wingate test (measured via COSMED Quark CPET system)
Time Frame: During the 30-second Wingate test
During the 30-second Wingate test
Heart Rate Responses during the 30-second Wingate test (measured via COSMED Quark CPET system)
Time Frame: During the 30-second Wingate test
During the 30-second Wingate test

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Manisa Celal Bayar University

Collaborators

The Scientific and Technological Research Council of Turkey

Investigators

  • Principal Investigator: ERKAN GUNAY, Prof.Dr., Manisa Celal Bayar University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 11, 2026

Primary Completion (Actual)

February 25, 2026

Study Completion (Actual)

February 25, 2026

Study Registration Dates

First Submitted

August 23, 2026

First Submitted That Met QC Criteria

August 26, 2026

First Posted (Actual)

September 1, 2026

Study Record Updates

Last Update Posted (Actual)

September 1, 2026

Last Update Submitted That Met QC Criteria

August 26, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MCBU_324S917_HV
  • 324S917 (Other Grant/Funding Number: TÜBİTAK)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Yes, de-identified participant data will be shared upon reasonable request to the corresponding author.

IPD Sharing Time Frame

Beginning 3 months and ending 5 years following article publication

IPD Sharing Access Criteria

Requests should be directed to the corresponding author via email

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe